At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 613 enrolled
Drug / intervention
Influenza Virus Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs
In Brief
A Phase 2 clinical trial evaluating Influenza Virus Vaccine for Influenza Disease; Flu. Completed, enrolled 613 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 \< 50 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Disease; Flu
CountriesUnited States
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
Primary CompletionDec 2005
First PostedDec 2005
Study CompletionMay 2006
TodayJul 2026
First PostedDec 13, 2005
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2005
Study CompletionMay 1, 2006
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 20.6 years ago
Interventions
Influenza Virus Vaccinebiological